Analysis of progression of number and structure of scans performed using PET, PET/ CT and PET/ MRI in the Czech Republic in 2013– 2021
Authors:
J. Adam 1,2; A. Svobodník 3; R. Štěpánová 3; D. Zogala 4; M. Havel 5; T. Büchler 6; M. Svoboda 1
Authors‘ workplace:
Masarykův onkologický ústav, Brno
1; ÚJV Řež, a. s.
2; Farmakologický ústav, LF MU Brno
3; Ústav nukleární medicíny 1. LF UK a VFN v Praze
4; Klinika nukleární medicíny LF OU a FN Ostrava
5; Onkologická klinika 2. LF UK a FN Motol, Praha
6
Published in:
Klin Onkol 2024; 38(4): 259-269
Category:
Original Articles
doi:
https://doi.org/10.48095/ccko2024259
Overview
Background: Positron emission tomography (PET) is a state-of-the-art diagnostic method of nuclear medicine, used for diagnostics of many pathological states in the organism, first and foremost in oncological issues. The first analysis of utilization and potential utilization of PET in the Czech Republic was published in 2013. In the following years, there was a sharp increase in a number of PET/CT and PET/MRI scanners in the country; in 2013–2021, it doubled. Simultaneously with the increase in scans performed, the range of available radiopharmaceuticals also broadened. Material and methods: The study analyses the numbers and structure of PET, PET/CT and PET/MRI scans in the 2013–2021 period, using the pseudonymized data acquired from the General Health Insurance Company of the Czech Republic. The data was evaluated through a series of qualitative and quantitative indicators (number of scans performed, structure of diagnoses, use of different tracers, and availability of a scan for a patient). Results: In the observed interval of time, the number of scans performed practically doubled, both thanks to more scanners installed and more radiopharmaceuticals available. The percentage of oncological and non-oncological scans remains more or less the same. Nevertheless, the regional differences in a number of scans performed persist, as does the availability of the scan for patients. Conclusion: PET is still a dynamically developing molecular imaging method in the Czech Republic. The analysis of a number and structure of scans performed offers a priceless overview of the development of the method over the years, in regard to diagnoses, utilization of individual radiopharmaceuticals or geographic distribution of scans performed. The observed findings are a motivation for further analyses.
Keywords:
Positron emission tomography – nuclear medicine – radiopharmaceuticals
Sources
1. Dušek L, Petera J, Doležal J et al. Predikce počtu pacientů indikovaných k vyšetření PET/CT v ČR: první výsledky projektu PET/CT-CZ (Q). Acta Medicinae 2014; 6: 30–34.
2. Všeobecná zdravotní pojišťovna ČR. Ročenky Všeobecné zdravotní pojišťovny ČR. [online]. Dostupné z: https: //www.vzp.cz/o-nas/dokumenty/rocenky.
3. Český statistický úřad. Demografická ročenka krajů – 2012–2021. [online]. Dostupné z: https: //www.czso.cz/csu/czso/demograficka-rocenka-kraju-2012- 2021.
4. ÚZIS ČR. PET/CT v diagnostice a kontrole léčby onkologických onemocnění, klinický doporučený postup. [online]. Dostupné z: https: //kdp.uzis.cz/res/ guideline/16-pet-ct-v-diagnostice-kontrole-lecby-onkologickych-onemocneni-souhrn.pdf.
5. European Comission, European Union. Eurostat Statistics explained. [online]. Available from: https: //ec.europa.eu/eurostat/statistics-explained/index.php?title=Healthcare_resource_statistics_-_technical_resources_and_medical_technology&oldid=452031#Use_of_medical_technology.
6. Adam J, Kadeřávek J, Kužel F et al. Techneciová krize – příčiny, možná řešení a dopad na diagnostiku planární scintigrafií a SPECT. Klin Onkol 2014; 27 (Suppl 1): 137–142. doi: 10.14735/amko20141S137.
7. Ferda J, Ferdová E, Matějka MV et al. Zobrazení kostních metastáz pomocí 18F-NaF-PET/CT. Ces Radiol 2011; 65 (1): 51–60.
8. Bělohlávek O, Fencl P, Majovský M. FLT-PET in previously untreated patients with low-grade glioma can predict their overall survival. Nucl Med Rev Cent East Eur 2014; 17 (1): 7–12. doi: 10.5603/NMR.2014. 0003.
9. Řehák Z, Bencsiková B, Zambo I et al. Fibrous dysplasia presenting as a cold spot in 18F-FLT PET/CT imaging. Clin Nucl Med 2016; 41 (6): 510–511. doi: 10.1097/RLU.000 0000000001209.
10. Vali R, Loidl W, Pirich C et al. Imaging of prostate cancer with PET/CT using 18F-fluorocholine. Am J Nucl Med Mol Imaging 2015; 5 (2): 96–108.
11. Zajíčková K, Zogala D, Kubinyi J. Parathyroid imaging by 18F-fluorocholine PET/CT in patients with primary hyperparathyroidism and inconclusive conventional methods: clinico-pathological correlations. Physiol Res 2018; 67 (Suppl 3): S551–S557. doi: 10.33549/physiolres.934029.
12. Čapoun O, Astua Elizondo K, Zogala D et al. Využití 18F‑fluciklovinu v detekci karcinomu prostaty při biochemické recidivě po radikální prostatektomii. Ces Urol 2021; 25 (1): 48–53.
13. Ptáčník V, Zogala D. PET/CT s 18F-fluciklovinem v diagnostice karcinomu prostaty. Urol praxi 2021; 22 (1): 5–8. doi: 10.36290/uro.2020.040.
14. Bělohlávek O, Jarůšková M. An easy way to increase confidence in beta-amyloid PET evaluation. J Nucl Med Rev Cent East Eur 2017; 20 (2): 107–109. doi: 0.5603/NMR.2017.0019.
15. Bělohlávek O, Jarůšková M, Skopalová M et al. Improved beta-amyloid PET reproducibility using two-phase acquisition and grey matter delineation. Eur J Nucl Med Mol Imaging 2019; 46 (2): 297–303. doi: 10.1007/s00259-018-4140-y.
16. Zogala D. PET somatostatinových receptorů nad rámec neuroendokrinních nádorů gastrointestinálního traktu – přehled literatury. Klin Onkol 2021; 34 (4): 291–299. doi: 10.48095/ccko2021291.
17. Budinský M, Vyšinský P, Synek S et al. 68Ga-DOTATOC. Ceska Slov Farm 2021; 70 (4): 136–141. doi: 10.5817/CSF2021-4-136.
18. Budinský M, Vyšinský P, Řehák Z et al. Zkušenosti s přípravou ⁶⁸Ga-PSMA-11. Chemické Listy 2022; 116 (12): 746–750. doi: 10.54779/chl20220746.
19. Novotný T, Řehák Z, Budinský M et al. Využití PET/CT s markerem hypoxie (18F-FMISO) v plánování radioterapie. Klin Onkol 2021; 34 (3): 241–243. doi: 10.48095/ccko202 1241.
20. Vašina J, Svoboda M, Lakomý R et al. Využití 11C--methioninu pro PET/ CT vyšetření pacientů s tumory mozku-soubor 16 pacientů. Nuclear Medicine/Nukleární Medicína 2018; 7 (4): 62–68.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2024 Issue 4
Most read in this issue
- The guidelines for clinical practice for carriers of germline mutations in hereditary breast, ovarian, prostate, and pancreatic cancer predisposition genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 (4.2024)
- Pancreatic cancer – epidemiology, risk factors, nutritional and infl ammatory prognostic and predictive factors
- Staging for endometrial carcinoma FIGO 2023 and its relevance for clinical practice
- Aktuální indikace neoadjuvantní a adjuvantní imunoterapie v léčbě nemalobuněčného karcinomu plic